|
| Monday, 9 March 2020, 14:46 HKT/SGT | |
| |
|
|
|
HONG KONG, Mar 9, 2020 - (ACN Newswire) - On 6 March 2020, a morale-enhancing conference themed "Working Towards a World-class High-tech ePark & a New Summit for Reform and Opening-up in the New Era" was held at Suzhou Industrial Park, during which leading companies and top professionals in the Park were recognised for their achievements. At the event, TOT BIOPHARM International Company Limited has garnered the 2019 "Listing Award of Technological Company" and the "Innovative Technological Research and Development Award".
Listed on the Stock Exchange of Hong Kong
Since its inception in Suzhou in July 2010, TOT BIOPHARM has its roots in the Park and continues to create innovations. It has focused on the development and commercialisation of innovative oncology drugs and treatments, with the aim of building a leading brand of oncology treatments trusted by patients and their families as well as medical professionals in China. In November 2019, the Company was listed on the Main Board of Hong Kong Stock Exchange under stock code: 1875.HK.
Innovative Technologies
TOT BIOPHARM has been increasing investments over the years. It has established an antibody drug production base with a designed production capacity of 16,000L. It has also focused on technological innovation and product development, and, to date, it has created various anti-tumour drug series and genres. Six drug candidates have entered key clinical trials or more advanced stages, thus forming a comprehensive high quality drug product chain.
The Company has also developed Perfusion-Batch Hybrid Technology ("PB-Hybrid Technology"), being the first to apply this technology to commercial production in China and completed production and testing and verification of various products and batches, thus creating a mature technology for itself. The technology has disrupted the traditional process of large-scale monoclonal antibody cell expansion. Capacity can be expanded from 25L to 2000L directly, and eliminate the 10L, 50L, 200L and 500L increments, thereby simplifying the process, optimising product quality, shortening the production cycle and reducing capital expenditures, providing remarkable competitive advantages in production.
TOT BIOPHARM has devoted several years of efforts to the development of Antibody Drugs Conjugates (ADC) technology. Recently the Group has completed the R&D, pilot production and release of Phase I clinical research data of its ADC drug TAA013. It has also completed the R&D and production of several next-generation ADC drugs for its strategic partners. TOT BIOPHARM's ADC drug production plant is currently under construction, and is to become one of the very few GMP-compliant ADC commercial production plants in China, hence laying a foundation for the Company to develop in the ADC area and to seize the first-mover opportunities in the market.
Open Co-operation Pursuit of Breakthroughs
TOT BIOPHARM has developed the layout of the entire industrial chain and established a comprehensive and integrated industrial chain platform comprising R&D, clinical trials, production and commercialization capabilities. It has actively opened its cooperation platforms in order to explore innovative drug development projects while also introducing more opportunities for innovation as it has vigorously pursued breakthroughs through international cooperation.
This accolade is recognition and acknowledgement of TOT BIOPHARM's development in recent years. In the future, TOT BIOPHARM will adhere to its business philosophy of striking a balance between humans and technology, continue to step up innovation efforts and forge continued success, with the aim of making further contributions to the treatment of disease as well as the business and economic development of Suzhou Industrial Park.
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25 
Apr 3, 2026 23:00 HKT/SGT
|
|
|
HKTDC's response to World Trade Organization's latest report
Apr 3, 2026 23:00 HKT/SGT
|
|
|
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Friday, April 3, 2026 11:33:00 AM
|
|
|
Hitachi Rail announces agreement to acquire Clever Devices, marking its growth as a global digital mobility player
Friday, April 3, 2026 10:09:00 AM
|
|
|
Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Apr 3, 2026 07:00 HKT/SGT
|
|
|
OMRON Healthcare and UCSF launch AFib trial
Thursday, April 2, 2026 11:00:00 PM
|
|
|
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo
Apr 2, 2026 19:00 HKT/SGT
|
|
|
Founders Metals Makes First Discovery at Antino North; Drills 17.22 g/t Au over 3.6 m within 24.6 m of 2.81 g/t Au
Apr 2, 2026 18:59 HKT/SGT
|
|
|
DENSO and FoodVentures Strengthen Collaboration through Capital Partnership in the Agricultural Sector
Thursday, April 2, 2026 6:56:00 PM
|
|
|
Luxury NEV Enterprise Seres Hits Record High Revenue of RMB164.89 Billion in 2025, Maintaining Positive Profitability for Second Consecutive Year
Apr 2, 2026 16:09 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
|
|
|
 |
|
